Generic Drug Market in Canada

Generic Drug Market in Canada

Canada is one of the world's largest pharmaceutical markets, even though it has a low share of only 3% in global pharma industry. In 2010, generics accounted for more than 57% prescriptions and around 26% sales of the total pharmaceutical market. On the back of factors including patent expiration of branded drugs, growing aging population, and government support through cost reduction measures, it is estimated that the market for generic drugs will be growing at a CAGR of around 13% during 2011-2014.

According to our latest market research report entitled, "Generic Drug Market in Canada", the provincial governments are implementing necessary steps to ensure the availability of drugs at an affordable cost. With billion dollars drug patents on the verge of expiry, the generic industry is foreseen to undergo a massive growth in the future. Besides, the government is adopting measures to enhance the supply proportion of generic drugs and rebates offered (to pharmacies) will augment revenue patterns of this industry.

Our report has identified that, neurological disorder therapy has shown an aggressive growth of 7.2% in 2010 over 2009, in terms of total prescription and the amount of prescriptions. However, oncology remained at the top position in terms of hospital sales with CAD 863.4 Million revenue in 2010, whereas the cardiovascular drugs have moved out from the list of top ten sales. Other therapy areas, such as anti-cholesterol agents and hypertension are expected to drive the generics market in Canada in future.

This report was compiled by considering all the requisite ingredients of Canadian generics sector and distinguishes domestic market from other generics market in all possible ways. The Canada generics market constitutes higher prices of generics and lower price erosion, in comparison to the US and most European markets, which makes it a major issue of concern for the government. However, the latest regulatory mechanism clearly shows that the Canadian Government has been adopting measures to ensure optimum generic costs.

"Generic Drug Market in Canada" provides extensive research and objective analysis of the generic drug market in Canada. The report effectively evaluates all the factors that are driving the growth and studies current market trends that will shape the future of the industry. The report also has cited the distribution of the drugs and presented state-wise consumptions to depict a much clear picture of the market. The report also examines the performance of various players in the Canadian pharmaceutical and generic markets. Besides, a number of factors that can prove to be deteriorative for the future growth of market have been discussed in the report.

Contents

• 1. Analyst View
• 2. Macroeconomic and Healthcare Factors
  • 2.1 Macroeconomic Indicators
  • 2.2 Population Profile
  • 2.3 Age Profile
  • 2.4 Healthcare Spending and Infrastructure
• 3. Market Trends
  • 3.1 More Generic Drugs for Hypertension
  • 3.2 Generics Getting Affordable
  • 3.3 Patent Expiration
• 4. Generics Market Performance
  • 4.1 Market Size and Growth
  • 4.1.1 Prescriptions
  • 4.1.2 Sales
  • 4.2 By Province/Territories
  • 4.2.1 Drug Consumption
  • 4.2.2 Prescriptions
  • 4.2.3 Sales
  • 4.3 By Distribution
  • 4.3.1 Retail Pharmacies
  • 4.3.2 Hospital Pharmacies
  • 4.3.3 Authorized and Independent Generics
  • 4.3.4 Distribution Channels
  • 4.4 By Disease
  • 4.4.1 Cardiovascular Drugs
  • 4.4.2 Psychotherapeutics
  • 4.4.3 Cholesterol Agents
  • 4.4.4 Neurological Agents
  • 4.4.5 Antidiabetics
• 5. Regulatory Environment
• 6. Competitive Landscape
  • 6.1 Market Structure
  • 6.2 Key Players Analysis
  • 6.2.1 Apotex
  • 6.2.2 Teva Canada Ltd. (Novopharm)
  • 6.2.3 Mylan
  • 6.2.4 Pharmascience
• List of Figures:
  • Figure 2-1: Nominal GDP (Billion US$), 2008-2010
  • Figure 2-2: Consumer Price Index (%), 2010-2014
  • Figure 2-3: Population (Million), 2010-2014
  • Figure 2-4: Life Expectancy (Years), 2010-2014
  • Figure 2-5: Population Breakup by Age Group (%), 2010-2014
  • Figure 2-6: Per Head Healthcare Spending (US$), 2010-2014
  • Figure 2-7: Number of Doctors (2010-2014)
  • Figure 2-8: Number of Hospital Beds (per '000 Population), 2010-2014
  • Figure 4-1: Pharmaceutical Sales (Billion CAD), 2010-2014
  • Figure 4-2: Prescriptions Dispensed in Branded Drugs Market (Million), 2006-2010
  • Figure 4-3: Prescriptions Dispensed in Generic Drugs Market (Million), 2006-2010
  • Figure 4-4: Share of Generic and Branded Drugs by Prescription (2006-2010)
  • Figure 4-5: Average Retail Price of Generic and Branded Drugs (CAD), 2006-2010
  • Figure 4-6: Generic Drug Sales (Billion CAD), 2010-2014
  • Figure 4-7: Branded Drug Sales (Billion CAD), 2010-2014
  • Figure 4-8: Share of Generic and Branded Drugs by Sales (2010-2014)
  • Figure 4-9: Branded Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
  • Figure 4-10: Generic Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
  • Figure 4-11: Share of Generic and Branded Drug Sales through Retail Pharmacies (2010-2014)
  • Figure 4-12: Branded Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
  • Figure 4-13: Generic Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
  • Figure 4-14: Share of Generic and Branded Drug Sales through Hospital Pharmacies (2010-2014)
  • Figure 4-15: Share of Independent Generic and Authorized Generic Prescriptions (2005-2008)
  • Figure 4-16: Generic Drugs Market by Retail and Hospital Sales (%), 2010
  • Figure 4-17: Cardiovascular Drug Market (Billion CAD), 2010-2014
  • Figure 4-18: Psychotherapeutics Market (Billion CAD), 2010-2014
  • Figure 4-19: Cholesterol Agents Market (Billion CAD), 2010-2014
  • Figure 4-20 Neurological Agents Market (Billion CAD), 2010-2014
  • Figure 4-21: Number of Diabetes Patients in Age Group 20-79 Years (Million), 2010 & 2030
  • Figure 4-22: Diabetes Therapy Market (Million CAD), 2010-2014
• List of Tables:
  • Table 3-1: Patent Expiration for Some Hypertension Drugs (2012)
  • Table 3-2: Patent Expiration of Key Drugs (2012)
  • Table 4-1: Top Ten Therapy Areas by Prescription ('000), 2010
  • Table 4-2: Per Capita Drug Spending of Public and Private Sector by Region (CAD), 2010
  • Table 4-3: Generic Drug Prescriptions Dispensed by Region (%), 2006-2010
  • Table 4-4: Generic Drug Sales by Region (%), 2006 & 2010
  • Table 4-5 Top Ten Therapy Areas by Retail Pharmacy Sales (Billion CAD), 2010
  • Table 4-6: Number of Retail Pharmacies by Category (2006-2011)
  • Table 4-7: Top Ten Therapy Areas by Hospital Sales (Million CAD), 2010
  • Table 6-1: Top Pharmaceutical Companies by Sales (Billion CAD), 2010
  • Table 6-2: Top Generic Drug Companies by Prescription (Million), 2007
  • Table 6-3: Top Generic Drug Companies by Sales (Million CAD), 2007
  • Table 6-4: Apotex - Strengths & Weaknesses
  • Table 6-5: Teva Canada Ltd. (Novopharm) - Strengths & Weaknesses
  • Table 6-6: Mylan - Strengths & Weaknesses

Related products

Antibiotics This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and...

Canada Pharmaceuticals and Healthcare Report Q4 2010 In BMI's Business Environment Ratings (BERs) for Q410, Canada remains in second place in the expanded regional matrix, trailing the US by around eight points. Globally, Canada ranks third of...

GenericHandbook - Third Edition (2009) A Guide to the Generic Drug Industry in the US NEW 3rd Edition GenericHandbook provides an in-depth, up-to-date analysis of the issues, trends, regulations, markets, companies and products in the U.S. generic drug industry. Topics covered include patent litigation, emerging...

Bosentan: Core Country Coverage Pipeline Selector Indications: Hypertension; Pulmonary arterial hypertension Innovator: Actelion (Tracleer) Pipeline Selector: single-drug access to essential competitor, regulatory and patent expiry information for quick and easy selection of your generics pipeline. Pipeline Selector...

Commercial Insight: Antipsychotics Revenues of depots and new agents will partially offset generic erosion In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in...

Global Generics Global generics market was valued at US$106.12 billion in 2008, registering a growth of 12.56% over the previous year, which is five times that of patented drugs. Cygnus estimates that...

PharmaHandbook: Volume One, Developed Market Sixth Edition (2009) DEVELOPED MARKETS (VOLUME I)Australia, Belgium, Canada, EU Combined, France, Germany, Greece, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Portugal, South Korea, Spain, Sweden, Switzerland, UK, USRegulatory Bodies • Approval Procedures...

Lercanidipine: Core Country Coverage Pipeline Selector Indications: Hypertension Innovator: Napp (Zanidip); Solvay (Zanidip) Pipeline Selector: single-drug access to essential competitor, regulatory and patent expiry information for quick and easy selection of your generics pipeline. Pipeline Selector is...

Pharmaceutical Pricing and Reimbursement Strategies for market access across the Us, Europe, Japan and other key geographies The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to...

Enfuvirtide: Core Country Coverage Pipeline Selector Indications: HIV-1 infection Innovator: Roche (Fuzeon) Pipeline Selector: single-drug access to essential competitor, regulatory and patent expiry information for quick and easy selection of your generics pipeline. Pipeline Selector is provided...

Canada Pharmaceuticals and Healthcare Report Q3 2011 BMI View: The Canadian pharmaceutical market is a refuge for the leading drugmakers. It is highly unlikely that punitive price controls like those witnessed across Europe over the past two...

Anti-Hypertensive Drugs This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million. The report provides separate comprehensive analytics for US, Europe and Rest of World. Annual forecasts are provided...

HIV Drugs This report analyzes the Worldwide markets for HIV Drugs in US$ Million. The report provides separate comprehensive analytics for US, Canada, Japan, Europe and Rest of World. Annual estimates...

Canada Pharmaceuticals and Healthcare Report Q2 2011 The primary threat to the Canadian economy in 2011-12 is the increasingly stretched state of household balance sheets, which will keep both private consumption and residential construction growth relatively muted...

Antibiotics Global Trends Long-term growth in the global antibiotics market would be affected by two major factors - antibiotic resistance and generic competition. Antibiotic resistance, which compels reduction in the usage of antibiotics,...

Bicalutamide: Core Country Coverage Pipeline Selector Indications: Prostate cancer Innovator: AstraZeneca (Casodex, Cosudex) Pipeline Selector: single-drug access to essential competitor, regulatory and patent expiry information for quick and easy selection of your generics pipeline. Pipeline Selector is...

Pricing & Reimbursement in Asia-Pacific Generic drugs (generics) are now an established part of pharmaceutical markets and healthcare policies around the world. According to IMS Health data, they already account for 63% of all prescriptions...

Pharmaceutical Pricing Global perspectives Pharmaceutical Pricing - Global Perspectives is a strategic report, that analyses all aspects of pharmaceutical pricing and reimbursement strategies through extensive use of case studies. The pricing of new pharmaceutical...

Pharmaceuticals The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird's eye view of the pharmaceutical...

Statins: The World Market 2011-2021 What will happen now in the statin drugs market? What does the future hold for the statins industry and market? Our new report shows how the patent expiry of Lipitor and...

Cardiovascular Drugs This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular...

Canada Pharmaceutical Industry The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical...

View all products in this category